Vascular endothelial growth factor expression in serous ovarian carcinoma: Relationship with high mitotic activity and high FIGO stage

Gynecologic Oncology

Volumn 84, Issue 1, 2002, Pages 47-52

  Brustmann, Hermann ^a   Naud́, Susanna ^a  

^a GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Cellular proliferation; FIGO stage; Mitotic activity; Ovarian tumors; Ovary; Serous ovarian cystadenocarcinomas; VEGF

Indexed keywords

ALKALINE PHOSPHATASE; EOSIN; HEMATOXYLIN; POLYCLONAL ANTIBODY; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER STAGING; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CYSTADENOCARCINOMA; CYSTADENOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0036142641     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6467     Document Type: Article

References (37)

1. The role of vascular endothelial growth factor in blood vessel formation
2. The biology of vascular endothelial growth factor
3. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
4. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
5. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
6. Identification of a new endothelial cell growth factor receptor tyrosine kinase
7. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
8. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study
9. Expression of vascular endothelial growth factor in primary superficial bladder cancer
10. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
11. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
12. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma
13. In vivo neutralisation of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth
14. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity
15. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystadenocarcinomas: Relationship with MIB 1 immunostaining
16. Toward the development of a universal grading system for ovarian epithelial carcinoma: Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up
17. Histopathologic grading of ovarian carcinoma: A review and proposal
18. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system
19. Expression of vascular permeability factor/vascular endothelial frowth factor by human granulosa and theca lutein cells
20. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms
21. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
22. Vascular endothelial growth factor expression in early stage ovarian carcinoma
23. Ki 67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: Index of proliferative activity, with prognostic significance
24. Vascular endothelial growth factor expression in malignant melanoma: Prognostic versus diagnostic usefulness
25. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
26. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
27. Secretion of vascular endothelial growth factor in ovarian cancer
28. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy
29. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
30. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary
31. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: A quantitative histologic study
32. Vascular endothelial growth factor and de novo mammalian angiogenesis
33. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
34. Validation of anti-vascular endothelial growth factor (anti-VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: Expression of VEGF in the human endometrium
35. Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate
36. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular growth factor receptor tyrosine kinase
37. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by chimeric antikinase insert domain-containing receptor antibody